DK1651622T3 - Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser - Google Patents

Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser

Info

Publication number
DK1651622T3
DK1651622T3 DK04780056T DK04780056T DK1651622T3 DK 1651622 T3 DK1651622 T3 DK 1651622T3 DK 04780056 T DK04780056 T DK 04780056T DK 04780056 T DK04780056 T DK 04780056T DK 1651622 T3 DK1651622 T3 DK 1651622T3
Authority
DK
Denmark
Prior art keywords
ylsulfonylamino
quinoxaline
preparation
benzamide compounds
benzamide
Prior art date
Application number
DK04780056T
Other languages
Danish (da)
English (en)
Inventor
Xiaohu Deng
Chennagiri R Pandit
Jimmy T Liang
Neelakandha Mani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1651622T3 publication Critical patent/DK1651622T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/42Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04780056T 2003-08-08 2004-08-04 Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser DK1651622T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08
PCT/US2004/025154 WO2005016897A1 (en) 2003-08-08 2004-08-04 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds

Publications (1)

Publication Number Publication Date
DK1651622T3 true DK1651622T3 (da) 2007-05-07

Family

ID=34193199

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04780055T DK1651621T3 (da) 2003-08-08 2004-08-04 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
DK04780056T DK1651622T3 (da) 2003-08-08 2004-08-04 Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04780055T DK1651621T3 (da) 2003-08-08 2004-08-04 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer

Country Status (33)

Country Link
US (3) US7288651B2 (de)
EP (2) EP1651621B1 (de)
JP (2) JP4818110B2 (de)
KR (1) KR20060060007A (de)
CN (2) CN1863781A (de)
AR (1) AR045930A1 (de)
AT (2) ATE353322T1 (de)
AU (2) AU2004265311A1 (de)
BR (1) BRPI0413449A (de)
CA (2) CA2534887A1 (de)
CR (1) CR8229A (de)
CY (1) CY1106486T1 (de)
DE (2) DE602004015614D1 (de)
DK (2) DK1651621T3 (de)
EA (1) EA200600203A1 (de)
EC (1) ECSP066355A (de)
ES (2) ES2310294T3 (de)
HR (1) HRP20080559T3 (de)
IL (1) IL173591A0 (de)
IS (1) IS8280A (de)
LT (1) LT5410B (de)
LV (1) LV13453B (de)
MX (2) MXPA06001482A (de)
NO (1) NO20061122L (de)
NZ (1) NZ545030A (de)
PL (2) PL1651622T3 (de)
PT (2) PT1651621E (de)
SG (1) SG131114A1 (de)
SI (2) SI1651621T1 (de)
TW (1) TW200521120A (de)
UA (1) UA84025C2 (de)
WO (2) WO2005016897A1 (de)
ZA (1) ZA200601946B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545030A (en) * 2003-08-08 2009-08-28 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino) -benzamide compounds as CCK2 modulators
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
BRPI0516027A (pt) 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv compostos de sulfonamida
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
JP5497429B2 (ja) * 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131245A3 (de) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithografische Vorrichtung und deren Fokusbestimmungsverfahren
US8354557B2 (en) * 2008-06-17 2013-01-15 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン,インコーポレイテッド 肥満治療に用いられるスルホン化合物
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
MX2014008705A (es) 2012-01-18 2015-02-05 Zafgen Inc Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2820010B1 (de) 2012-03-01 2018-05-09 Allergan, Inc. Benzofuran-2-sulfonamid derivate als chemokin rezeptor modulatoren
CA2890344A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
KR20150079952A (ko) 2012-11-05 2015-07-08 자프겐 인크. 트리시클릭 화합물 및 그의 제조 및 사용 방법
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
PL3071206T3 (pl) 2013-11-22 2022-01-17 CL BioSciences LLC Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
WO1995004720A2 (en) * 1993-08-10 1995-02-16 Black James Foundation Gastrin and cck receptor ligands
AU721081B2 (en) 1996-12-10 2000-06-22 Zeria Pharmaceutical Co., Ltd. 1,5-benzodiazepine derivatives
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
NZ545030A (en) * 2003-08-08 2009-08-28 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino) -benzamide compounds as CCK2 modulators
BRPI0516027A (pt) * 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv compostos de sulfonamida

Also Published As

Publication number Publication date
LT5410B (lt) 2007-03-26
ES2281834T3 (es) 2007-10-01
JP2007501841A (ja) 2007-02-01
EA200600203A1 (ru) 2006-08-25
EP1651621A1 (de) 2006-05-03
CA2534885C (en) 2013-06-04
JP2007501842A (ja) 2007-02-01
CA2534887A1 (en) 2005-02-24
CN1863782A (zh) 2006-11-15
CA2534885A1 (en) 2005-02-24
DE602004015614D1 (de) 2008-09-18
EP1651622B1 (de) 2007-02-07
LT2006017A (en) 2006-11-27
AR045930A1 (es) 2005-11-16
SI1651621T1 (sl) 2008-12-31
NO20061122L (no) 2006-05-04
DK1651621T3 (da) 2008-11-10
CN1863781A (zh) 2006-11-15
DE602004004663D1 (de) 2007-03-22
PT1651622E (pt) 2007-04-30
MXPA06001482A (es) 2006-09-04
WO2005016897A1 (en) 2005-02-24
CR8229A (es) 2008-09-10
JP4818110B2 (ja) 2011-11-16
BRPI0413449A (pt) 2006-10-17
KR20060060007A (ko) 2006-06-02
HRP20080559T3 (en) 2009-01-31
EP1651622A1 (de) 2006-05-03
DE602004004663T2 (de) 2007-11-22
AU2004265312A1 (en) 2005-02-24
CY1106486T1 (el) 2012-01-25
IL173591A0 (en) 2006-07-05
MXPA06001550A (es) 2006-09-04
US20050038032A1 (en) 2005-02-17
US20050043310A1 (en) 2005-02-24
AU2004265312B2 (en) 2010-05-20
TW200521120A (en) 2005-07-01
SI1651622T1 (sl) 2007-06-30
NZ545030A (en) 2009-08-28
US7563895B2 (en) 2009-07-21
IS8280A (is) 2006-01-31
WO2005016896A1 (en) 2005-02-24
ZA200601946B (en) 2007-05-30
SG131114A1 (en) 2007-04-26
US7304051B2 (en) 2007-12-04
ATE403650T1 (de) 2008-08-15
ATE353322T1 (de) 2007-02-15
PT1651621E (pt) 2008-09-30
US20080076918A1 (en) 2008-03-27
US7288651B2 (en) 2007-10-30
UA84025C2 (en) 2008-09-10
PL1651622T3 (pl) 2007-07-31
AU2004265311A1 (en) 2005-02-24
EP1651621B1 (de) 2008-08-06
LV13453B (en) 2007-02-20
ECSP066355A (es) 2006-08-30
ES2310294T3 (es) 2009-01-01
PL1651621T3 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1611108T3 (da) Fremgangsmåde til fremstilling af telmisartan
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1567482T3 (da) Fremgangsmåde til fremstilling af phenylmalonsyre-dinitriler
DK1963251T3 (da) Fremgangsmåde til fremstilling af aminer
DK1407037T3 (da) Fremgangsmåde til fremstilling af tagatose
DK1578731T3 (da) Fremgangsmåde til fremstilling af pyrimidinforbindelser
DK1805316T3 (da) Fremgangsmåde til fremstilling af de enantiomere former af cis-3-hydroxycy-
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
DK1519928T3 (da) Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1682541T3 (da) Fremgangsmåde til fremstilling af tiotropiumsalte
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
DK1660485T3 (da) Forbedret fremgangsmåde til fremstilling af alpha-polymorfisk eletriptanhydrobromid
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer
DK1503995T3 (da) Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer